What can HIV vaccine trials teach us about future HIV vaccine dissemination?

Vaccine

Volumn 26, Issue 20, 2008, Pages 2528-2536

  Newman, Peter A ^a   Duan, Naihua ^b   Kakinami, Lisa ^c   Roberts, Kathleen ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acceptability; Clinical trials; Ethnic minorities; HIV vaccines; Qualitative research; Willingness to participate

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; COUNSELING; DRUG EFFICACY; EDUCATION; ETHNICITY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SAMPLING; THEMATIC ANALYSIS; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; FOCUS GROUPS; HUMANS; LOS ANGELES; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; VACCINATION;

EID: 42649084319     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.004     Document Type: Article

References (30)

1. International AIDS Vaccine Initiative (IAVI). The state of global research. 2007. (Accessed November 28, 2007, at http://www.iavi.org/viewpage.cfm?aid=12).
2. Esparza J, Chang ML, Widdus R, Madrid Y, Walker N, Ghys PD. Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). Vaccine 2003; 21:2041-2050.
3. Chang ML, Vitek C, Esparza J. Public health considerations for the use of a first generation HIV vaccine. Report from a WHO-UNAIDS-CDC consultation, Geneva, 20-21 November 2002. AIDS 2003; 17:W1-10.
4. Newman P.A., Duan N., Rudy E.T., and Anton P.A. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it will they come?. AIDS Patient Care STDS 18 (2003) 691-701
5. Newman P.A., Duan N., Lee S.J., Rudy E.T., Seiden D.S., Kakinami L., et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine 24 (2006) 2094-2101
6. Institutes of Medicine. Calling the shots: immunization finance policies and practices. (2000), National Academy Press, Washington
7. Herek G.M., Capitanio J.P., and Widaman K.F. HIV-related stigma and knowledge in the United States: prevalence and trends, 1991-1999. Am J Public Health 92 (2002) 371-377
8. Duan N. Listening to consumers and HIV vaccine preparedness. Lancet 365 9465 (2005) 1119-1121
9. Gifford A.L., Cunningham W.E., Heslin K.C., Andersen R.M., Nakazono T., Lieu D.K., et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 346 (2002) 1373-1382
10. Anderson R., and Hanson M. Potential public health impact of imperfect HIV type 1 vaccines. J Infect Dis 191 (2005) S85-S96
11. Blower S.M., and McLean A.R. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 265 (1994) 1451-1454
12. Newman P.A., Duan N., Rudy E.T., Roberts K.J., and Swendeman D. Posttrial HIV adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr 37 (2004) 393-1403
13. Crosby R.A., Holtgrave D.R., Bryant L., and Frew P.M. Factors associated with the acceptance of an AIDS vaccine: an exploratory study. Prev Med 39 (2004) 804-808
14. Liau A., Zimet G.D., and Fortenberry J.D. Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics. Sex Transm Dis 25 (1998) 76-81
15. Newman P.A., Duan N., Rudy E.T., and Johnston-Roberts K. HIV risk and prevention in a post-vaccine context. Vaccine 22 (2004) 1954-1963
16. Zimet G.D., Blythe M.J., and Fortenberry J.D. Vaccine characteristics and acceptability of HIV immunization among adolescents. Int J STD AIDS 11 (2000) 143-149
17. Mills E., Cooper C., Guyatt G., Gilchrist A., Rachlis B., Sulway C., et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 18 (2004) 2235-2242
18. Morgan D.L. The focus group guidebook (1998), Sage Publications, Thousand Oaks, California
19. Marin G., and Marin BV. Research with Hispanic populations. (1991), Sage Publications, Newbury Park, California
20. Charmaz K.C. Constructing grounded theory: a practical guide through qualitative analysis. (2006), Sage Publications, London
21. Brooks R., Newman P.A., Duan N., and Ortiz D. HIV vaccine trial preparedness among Spanish-speaking Latinos in the United States. AIDS Care 19 1 (2007) 52-58
22. Newman P.A., Duan N., Roberts K.J., Seiden D.S., Rudy E.T., Swendeman D., et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr 41 (2006) 210-217
23. Levy J.A. What can be achieved with an HIV vaccine?. Lancet 357 9251 (2001) 223-224
24. Blower S., Schwartz E.J., and Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies and imperfect vaccines. AIDS Rev 5 (2003) 113-125
25. Roberts K.J., Newman P.A., Duan N., and Rudy E.T. HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. J Nat Med Assn 97 (2005) 1662-1671
26. Rudy E.T., Newman P.A., Duan N., Kelly E.M., Roberts K.J., and Seiden D.S. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev 17 (2005) 253-267
27. Newman P.A., Daley A., Halpenny R., and Loutfy M. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 26 (2008) 1091-1097
28. HIV Vaccine Trials Network. Vaccination and enrollment are discontinued in phase II trials of Merck's investigational HIV vaccine candidate [Internet]. Whitestation (NJ). Available from: http://www.hvtn.org/pdf/FINAL_HIV_Vaccine_Press_Release.pdf.
29. Buchbinder S.P., Metch B., Holte S.E., Scheer S., Coletti A., and Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 36 (2004) 604-612
30. Halpern S.D., Metzger D.S., Berlin J.A., and Ubel P.A. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr 27 (2001) 281-288